Latest Content

In the latest installment of CURE's "Text a Survivor" series, Brad Moore answers some of the most common questions people have about living with and beyond a colorectal cancer diagnosis.

Lyrfigtu was approved for adults with previously treated cholangiocarcinoma with an FGFR2 gene fusion or other rearrangement.

Researchers are studying whether combining CAR-T cell therapy with targeted drugs could help children with high-risk leukemia, including infants whose cancer may be more likely to return after treatment.

Mindfulness-based cancer recovery and Tai Chi/Qigong improved fatigue and how much pain interfered with daily life among cancer survivors experiencing distress, while Tai Chi/Qigong also improved sleep quality.

A breast cancer survivor reflects on the complicated meaning of pink, remembering what cancer took, those still fighting and the people behind the ribbon.

Paxalisib, first studied in brain cancer, may help HR+ breast tumors respond to CDK4/6 inhibitors again, based on early lab data.

A cancer survivor shares what to say, what not to say and how listening can help support someone through cancer treatment and beyond.

Bravnetsa is the first radioligand therapy approved through the FDA's abbreviated pathway, adding an option for adults with SSTR-positive GEP-NETs.

The investigational drug, first developed for brain cancer, is being tested to see whether it can make resistant tumors respond to treatment again.

AI is becoming a growing part of cancer care. Learn how doctors are using it to navigate complex treatment decisions and support patients.

In patients with advanced ROS1-positive lung cancer who had not previously received a ROS1-targeted drug, Jideytro also shrank tumors that had spread to the brain in all 10 evaluable patients.

An estimated 70% of patients with stage 3 lung cancer do not see their tumors respond to standard treatment. An expert explains why, and what a new approach aims to change.

Living with stage IV kidney cancer for 10 years, one survivor shares how he manages scanxiety, uncertainty and the waiting between scans.